STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis

Quraishi, M. N. N. et al. (2019) STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis. BMJ Open, 9(11), e030659. (doi: 10.1136/bmjopen-2019-030659) (PMID:31719078) (PMCID:PMC6858155)

[img] Text
204180.pdf - Published Version
Available under License Creative Commons Attribution.



Introduction: Imbalance of the gut microbiome is key to the pathogenesis of ulcerative colitis (UC). Faecal microbiota transplant (FMT) is the transfer of homogenised and filtered faeces from a healthy individual to the gastrointestinal tract of a patient with disease. Published datasets show a positive signal for the use of FMT to treat UC, but the optimal route and dose of FMT remain unanswered. Methods and analysis: This prospective, multi-centre open-label, randomised pilot study will assess two possible routes of FMT delivery, via the nasogastric (NG) route or by delivery to the COLON, in 30 patients with active UC recruited from three sites in the UK. Stool will be collected from healthy screened donors, processed, frozen and stored under a Medicines and Healthcare products Regulatory Agency (MHRA) “specials” manufacturing licence held at the University of Birmingham Microbiome Treatment Centre. Thawed FMT samples will be administered to patients either via eight nasogastric infusions given initially over 4 days starting on the day of randomisation, and then again for 4 days in week 4 for foregut delivery (total of 240 g of stool) or via one colonoscopic infusion followed by seven weekly enemas according to the hindgut protocol (total of 360 g of stool). Patients will be followed up weekly for 8 weeks, and then at 12 weeks. The aims of this pilot study are (1) to determine which FMT administration route (NG or COLON) should be investigated in a randomised double-blind, placebo-controlled trial and (2) to determine if a full randomised controlled trial is feasible. The primary outcome will be a composite assessment of both qualitative and quantitative data based on efficacy (clinical response), acceptability and safety. At the end of the pilot study, decisions will be made regarding the feasibility of a full randomised double-blind, placebo-controlled trial and, if deemed feasible, which route of administration should be used in such a study. Ethics and dissemination: Ethical approval for this study has been obtained from the East Midlands-Nottingham Research Ethics Committee (REC 17/EM/0274). At the end of the study, findings will be reported at national and international gastroenterology meetings and published in peer-reviewed journals. Trial registration number: ISRCTN74072945

Item Type:Articles
Additional Information:This study is funded by the National Institute for Health Research (NIHR) as part of the Efficacy and Mechanism Evaluation (EME) programme.
Glasgow Author(s) Enlighten ID:Hansen, Dr Richard and Gaya, Mr Daniel and Gerasimidis, Professor Konstantinos
Authors: Quraishi, M. N. N., Yalchin, M., Blackwell, C., Segal, J., Sharma, N., Hawkey, P., McCune, V., Hart, A. L., Gaya, D., Ives, N. J., Magill, L., Loi, S., Hewitt, C., Gerasimidis, K., Loman, N. J., Hansen, R., McMullan, C., Mathers, J., Quince, C., Crees, N., and Iqbal, T.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:BMJ Open
Publisher:BMJ Publishing Group
ISSN (Online):2044-6055
Published Online:11 November 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in BMJ Open 9(11): e030659
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record